Market Research Blog – Page 2164 – New Product Development

Global Urinary Tract Infection Treatment Industry Poised for Steady Growth at 1.9% CAGR, Reaching US$13.62 Billion by 2034 | FMI

The Global Urinary Tract Infection Treatment Industry is on track for consistent growth, driven by rising prevalence and ongoing developments in treatment options. According to a recent market analysis, the market was valued at an estimated US$11.24 billion in 2024 and is projected to reach US$13.62 billion by 2034. This translates to a Compound Annual Growth Rate (CAGR) of 1.9%.

The urinary tract infection treatment market is poised for substantial growth in the foreseeable future, attributed to factors such as hormonal changes, inadequate personal hygiene practices, catheter usage, and other contributing factors. As the prevalence of urinary tract infections rises, the market is anticipated to experience noteworthy expansion in the coming years.

The heightened occurrence of chronic kidney diseases, including conditions like bladder cancer and renal failure, has resulted in a greater utilization of catheters and other drainage devices among patients. Individuals using urinary catheters face an elevated risk of developing complicated urinary tract infections, driving the demand for UTI treatment.

Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-1340

Supportive government policies, initiatives, and regulations can influence the market positively by fostering research and development in the field of UTI treatment. Increased spending on healthcare infrastructure and services, both in developed and developing countries, can positively influence the UTI treatment market.

The adoption of telehealth and remote patient monitoring technologies can facilitate better management and follow-up care for individuals with UTIs. Growing awareness among patients and healthcare professionals about the importance of early detection and prompt treatment of UTIs can contribute to market growth.

Global Urinary Tract Infection Treatment Industry Key Takeaways

From 2019 to 2023, the urinary tract infection (UTI) treatment market was valued at a CAGR of 2.1%
Based on indication, the uncomplicated UTI segment is expected to account for a share of 76.2% in 2024.
urinary tract infection (UTI) treatment demand in China is predicted to account for 2% in 2024.
In the United States, the urinary tract infection (UTI) treatment industry is expected to account for a CAGR of 2.5% in 2024.
India is projected to expand by a value CAGR of 1.9% between 2024 and 2034.
The urinary tract infection (UTI) treatment market in Japan is anticipated to record a CAGR of 2.1% in 2024.

“Increased prevalence of urinary tract infections and strategic advancements in treatment options propel the growth of the urinary tract infection treatment market.” says an FMI analyst.

Global Urinary Tract Infection Treatment Industry Competitive Landscape

The market players are investing in ongoing research and development activities to discover and develop new and more effective UTI treatment options. This could involve the exploration of novel antibiotics, combination therapies, and innovative drug delivery methods. Expanding market presence by entering new geographic regions and enhancing distribution networks to ensure wider availability of UTI treatments.

Bristol-Myers Squibb Company focuses on the development of drugs in various therapeutic areas, including infectious diseases. They might have products related to UTI treatment.
Janssen Global Services LLC is a pharmaceutical company under the umbrella of Johnson & Johnson. They may have products related to infectious diseases, including UTI treatment.
Lupin is an Indian multinational pharmaceutical company. They might have a range of pharmaceutical products, including those related to infectious diseases.

More Valuable Insights Available

Future Market Insights offers an unbiased analysis of the global urinary tract infection (UTI) treatment market, providing historical data from 2019 to 2023 and forecast statistics between 2024 and 2034.

To understand opportunities in the urinary tract infection (UTI) treatment industry, the industry is segmented based on Drug Class (Penicillin & Combinations, Quinolones, Cephalosporin, Aminoglycoside Antibiotics, Sulphonamides (Sulfamethoxazole, Trimethoprim), Azoles and Amphotericin B, Tetracycline (Doxycycline), Nitrofurans (Nitrofurantoin), Others) By Indication(Complicated Urinary Tract Infection, Uncomplicated Urinary Tract Infection) By Distribution Channel(Hospital Pharmacies, Gynecology and Urology Clinics, Drug Stores, Retail Pharmacies, Online Drug Stores) Region (North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia, and the Middle East and Africa).

Key Players operating in the Global Urinary Tract Infection Treatment Industry are

Allergan
Bayer AG
Pfizer, Inc.
GlaxoSmithKline plc
Bristol-Myers Squibb Company
Janssen Global Services, LLC
Lupin Ltd
Merck & Co., Inc.
Almirall, S.A
Dr. Reddy’s Laboratories Ltd.

Click Here To Buy Your Full Report
https://www.futuremarketinsights.com/checkout/1340

Global Urinary Tract Infection Treatment Industry – Key Segments

By Drug Class:

Penicillin & Combinations
Quinolones
Cephalosporin
Aminoglycoside Antibiotics
Sulphonamides (Sulfamethoxazole, Trimethoprim)
Azoles and Amphotericin B
Tetracycline (Doxycycline)
Nitrofurans (Nitrofurantoin)
Others

By Indication:

Complicated
Uncomplicated

By Distribution Channel:

Hospital Pharmacies
Gynecology and Urology Clinics
Drug Stores
Retail Pharmacies
Online Drug Stores

By Region:

North America
Latin America
Western Europe
Eastern Europe
South Asia and the Pacific
East Asia
Middle East and Africa

About the Healthcare Division at Future Market Insights

The healthcare team at Future Market Insights offers expert analysis, time-efficient research, and strategic recommendations to provide authentic insights and accurate results to help clients worldwide.

With a repertoire of over 100+ reports and 1 billion+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis of key trends including competitive landscape, profit margin, and research development efforts.

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Empty Capsules Industry Booming: Set to Reach US$6.38 Billion by 2034 at 8% CAGR | FMI

The Global Empty Capsules Industry is on an upswing, driven by the rising burden of chronic diseases and the growing popularity of dietary supplements. According to a recent market analysis, the market is expected to reach a value of US$2,956.6 million in 2024. Looking ahead, it’s projected to climb at an impressive Compound Annual Growth Rate (CAGR) of 8% from 2024 to 2034. By 2034, the market is expected to reach a staggering US$6,378.6 million, signifying a significant opportunity for stakeholders within the industry.

The surge in demand for empty capsules can be attributed to the escalating frequency of chronic diseases and the increasing popularity of dietary supplements. Recognized as a swift and convenient method for drug consumption, empty capsules offer a hassle-free alternative, less prone to induce adverse effects compared to other dose forms.

Driving Factors Behind Surging Demand for Global Empty Capsule Industry

The primary drivers behind the surging demand for empty capsules are twofold. First, there is a noticeable uptick in the popularity of capsules as the preferred form of drug delivery. This shift is further accentuated by the increasing consumption of various medications. Secondly, as the global burden of chronic diseases continues to escalate, the demand for effective therapeutics is expected to surge, presenting lucrative opportunities for suppliers of empty capsules.

Request a Sample Copy of This Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-782

A Promising Future for the Global Empty Capsules Industry

In summary, the future of the Global Empty Capsules Industry appears incredibly promising, with robust growth prospects anticipated in the years ahead. Key industry players operating in the market are well-positioned to benefit from this trend, provided they adapt to evolving consumer preferences and invest in product innovation to maintain a competitive edge.

Empty capsules are known as protective shells for drugs designed from special film-forming materials such as gelatin, starch, and pullulan. Being innovative drug delivery products, they are utilized by leading pharmaceutical and biopharmaceutical companies due to their various attractive features. Such capsules are economical, oxidation resistant, offer maximum flexibility, and are easy to use on account of their smooth and slippery nature. Furthermore, they are especially suitable for substances having a bitter taste and unpleasant odor.

Global Empty Capsule Industry Key Takeaways

Unprecedented Growth: The global empty capsule market is projected to reach a significant value of US$ 2,956.6 million in 2024, with a compelling 8% Compound Annual Growth Rate (CAGR) expected from 2024 to 2034, ultimately reaching US$ 6,378.6 million by 2034.
Rising Demand Due to Chronic Diseases: The increasing prevalence of chronic diseases worldwide is a major driving force behind the surge in demand for empty capsules. These capsules offer an efficient and convenient method for drug consumption, catering to the needs of patients and healthcare providers alike.
Popularity of Dietary Supplements: The industry is experiencing a spike in demand, driven by the growing popularity of dietary supplements. Empty capsules are recognized as a preferred choice for the delivery of supplements, contributing to the overall growth of the market.
Ease of Use and Reduced Side Effects: Empty capsules provide a quick and easy means of drug consumption and are less likely to induce negative effects compared to other dose forms. This inherent advantage is further propelling the increased adoption of empty capsules in the pharmaceutical and healthcare sectors.
Paradigm Shift in Drug Formulation: As the market expands, there is a noticeable shift in the pharmaceutical and nutraceutical sectors towards embracing the benefits of empty capsules for drug formulation. This shift indicates a changing landscape in the way drugs are developed and delivered.
Strategic Implications for Stakeholders: Stakeholders in the pharmaceutical and healthcare sectors are advised to recognize and adapt to the dynamic landscape of the empty capsule market. With a projected market value of US$ 6,378.6 million by 2034, staying informed about industry trends and innovations is crucial for staying competitive.
Transformative Journey Ahead: The global empty capsule market is on the verge of a transformative journey, and industry players should proactively position themselves to capitalize on the opportunities presented by this substantial growth in the coming decade.

Global Empty Capsule Industry Competitive Landscape

The Global Empty Capsules Industry is known to be highly competitive in nature attributed to the presence of leading empty pill manufacturers that account for over 70% of the global market share. Prominent market players are constantly focusing on introducing new products designed out of innovative materials. In addition to that, they are adopting growth strategies such as partnerships, mergers, acquisitions, etc. to expand their global footprint.

List encompassing key players operating in the Global Empty Capsules Industry

ACG Worldwide
Capsugel
Qualicaps Inc.
Bright Pharma Caps Inc.
Sunil Healthcare Ltd.
CapsCanada Corporation
Roxlor LLC
Snail Pharma Industry Co. Ltd.
Suheung Co. Ltd.
Medi-Caps Ltd

Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/782

Key Segments of Global Empty Capsules Industry Survey

Capsule Size:

Size “000” Empty Capsules
Size “00” Empty Capsules
Size “0” Empty Capsules
Size “1” Empty Capsules
Size “2” Empty Capsules
Size “3” Empty Capsules
Size “4” Empty Capsules
Size “5” Empty Capsules

Product Type:

Gelatin (Hard)-based Capsules
Vegetarian-based Capsules

Route of Administration:

Empty Capsules for Oral Administration
Empty Capsules for Inhalation

Raw Material:

Contract Type-A (Pork Skin) Empty Capsules
Type-B Gelatin (Animal Bones & Calf Skin) Empty Capsules
Fish Bone Gelatin Empty Capsules
Empty Hydroxy Propyl Methyl Cellulose (HPMC) Empty Capsules
Starch Material Empty Capsules
Empty Pullulan Capsules

End User:

Empty Capsules for Pharmaceutical Companies
Empty Capsules for Cosmetic & Nutraceutical Companies
Empty Capsules for Clinical Research Organizations (CROS)

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Global Wearable Medical Device Industry Set for Steady Growth at 8.2% CAGR, Reaching US$84.8 Billion by 2034 | FMI

The Global Wearable Medical Device Industry is poised for a remarkable surge, according to a recent market analysis by Future Market Insights (FMI). The market, valued at US$38.58 billion in 2024, is projected to reach a staggering US$84.85 billion by 2034. This translates to a robust Compound Annual Growth Rate (CAGR) of 8.20% over the next decade, highlighting the increasing adoption of these innovative healthcare solutions.

This significant expansion is fueled by a paradigm shift in healthcare, driven by the rising prevalence of chronic diseases and the growing trend of sedentary lifestyles. Traditional healthcare models are being reevaluated as governments, healthcare organizations, and medical service providers prioritize early diagnosis and regular patient monitoring.

Wearable medical devices are emerging as a pivotal solution to address these challenges, offering continuous monitoring and real-time data collection. This trend is further accelerated by the active encouragement of routine diagnosis by regional and national healthcare agencies through awareness programs and various campaigns. These initiatives are fostering heightened awareness among the masses regarding the benefits of wearable medical devices for monitoring and diagnosing vital signs.

Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-826

Key Takeaways from the Global Wearable Medical Device Industry Report

The wearable medical device market achieved a market size of US$ 36,604.3 million in 2023. During the historical period, the market registered a CAGR of 7%.
By product, the wearable therapeutic medical device segment is estimated to acquire a value share of 55% in 2024.
Based on the application, the home healthcare segment is anticipated to obtain a market share of 63% in 2024.
The wearable medical device industry in the United States is expected to expand at a CAGR of 5% through 2034.
The wearable medical device market in France is projected to register a CAGR of 8% from 2024 to 2034.
The wearable medical device market in India is estimated to record a staggering CAGR of 40% over the forecast period.
The market in Singapore is projected to grow at a CAGR of 10% through 2034.

“Continuous advancements and release of upgraded wearable medical devices by leading players are expected to be a go-to-market strategy of leading players. Additionally, players are expected to explore the potential of wearable medical devices in various new segments,” says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)

Competitive Landscape in the Global Wearable Medical Device Industry

Market players are developing advanced wearables and exploring new application cases for wearable medical devices, which is contributing to market growth. The industry participants are acquiring firms with complementary technologies and collaborating with other healthcare institutions, technology providers, and pharmaceutical firms to expand their distribution channels, leverage expertise, and develop integrated solutions.

Players are further emphasizing privacy and data security and prioritizing user-friendly designs to boost user adoption and compliance. Industry participants are getting involved in targeted marketing campaigns toward certain healthcare professionals and patient segments to elevate brand recognition and drive device adoption.

Recent Developments in the Global Wearable Medical Device Industry

In July 2023, Dexcom, a developer of constant glucose monitors, revealed that it is making a Type 2 diabetes monitor for patients who don’t require insulin. The company also offers a cash-pay choice for patients not secured by health insurers and Medicare.
In July 2023, Samsung announced that it is gearing up to launch the ‘Galaxy Ring’ equipped with smart health features in 2024. For the success of its recent wearable endeavor, the Korean tech giant is collaborating with international as well as domestic component manufacturers.

Manufacturers of the Global Wearable Medical Device Industry

Medtronic plc
Siemens AG
Fitbit Inc.
Bayer AG
Panasonic Corporation
Animas Corporation – Johnson and Johnson
Smiths Medical – A Smiths Group Company
Koninklijke Philips N.V.
Owlet Baby Care
OMRON Corporation
Hoffmann-La Roche Ltd
Rest Devices Inc.
Others

Click Here To Buy Your Full Report https://www.futuremarketinsights.com/checkout/826

Global Wearable Medical Device Industry Segmentation

By Product:

Wearable Monitoring and Diagnostic Devices
Fetal and Obstetric Devices
- Wearable Foetal Monitors
- Infant Motion Sensing Monitors
Continuous Glucose Monitoring Devices
Cardiac Monitoring Devices
- Wearable Heart Rate Monitors
- Wearable Pulse Oximeters
- Wearable Blood Pressure Monitors
Wearable Therapeutic Medical Device
Hearing Aid
Insulin Pump
Respiratory Therapy Devices
- Sleep Apnea Devices
- Non-invasive Ventilation
Health and Fitness Devices

By Application:

Patient Monitoring
Home Healthcare
Health and Fitness

By Distribution Channel:

Hospital Pharmacies
Clinics
Online Channels
Hypermarkets

By Region:

North America
Europe
Asia Pacific
Middle East and Africa
Latin America

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Global Electronic Medical Records Industry Set for Steady Growth, Reaching US$34.34 Billion by 2034 at 6.2% CAGR | FMI

The Global Electronic Medical Records Industry is on track for significant expansion, with a projected market value of US$34.34 billion by 2034. This translates to a healthy Compound Annual Growth Rate (CAGR) of 6.2% anticipated from 2024 to 2034. The current market size is estimated to be US$18.82 billion in 2024, highlighting the increasing adoption of these digital healthcare solutions.

As healthcare organizations worldwide recognize the imperative benefits of electronic medical records, the market is expected to witness substantial expansion. The heightened demand is directly correlated to the industry’s recognition of electronic health records as software-as-a-service, facilitating scalability and streamlined operations for multiple healthcare providers.

Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-387

The market is expanding as a result of an increase in the number of benefits, including lower infrastructure and maintenance expenses, lower license and start-up costs, and greater accessibility. Improved productivity and quicker, simpler adoption are two benefits of cloud-based EMR solutions. The application is incredibly scalable because of its cloud-based architecture (pay-as-you-go storage utilization). It removes departmental silos of healthcare data to streamline and consolidate storage resources to reduce costs and boost efficiency.

Large, well-known firms are starting to enter the cloud sector. To maintain the level of patient care, the cloud infrastructure also provides real solutions for business continuity and disaster recovery. As a result, the cloud-based EMR market is anticipated to expand dramatically. The digital revolution in healthcare is essential to give medical staff relatively easy access to patient records. During the projection period, it is predicted that the growing need for systems and software that connect hospitals, clinics, and other healthcare facilities will become a growth driver.

A greater emphasis is placed on strategic partnerships between leading suppliers of electronic medical record solutions as market rivalry intensifies. Additionally, it is projected that the constantly growing need for knowledge sharing and technology upgrades to improve healthcare efficiency will foster partnerships between important actors.

Key Takeaways from the Global Electronic Medical Records Industry

The US electronic medical records (EMR) market is anticipated to expand at a CAGR of 4.5% over the forecasted period.
The market for electronic medical records (EMR) in India is anticipated to expand at 6.8% over the forecasted period.
By 2033, the market for electronic medical records (EMR) is anticipated to reach more than US$ 34.34 billion
In 2021, the market for electronic medical records (EMR) was dominated by cloud-based EMRs, which accounted for more than 50.0% of total revenue.
Hospital electronic medical records (EMR) are expected to increase at a CAGR of 6.4% throughout the forecast period as a result of rising pandemic and epidemic infections, as well as the requirement for global vaccination against a wide range of diseases.

Who is Winning?

According to Future Market Insights (FMI), top EMR solution providers are building alliances with the local healthcare system, engaging in mergers and acquisitions, and bolstering their distribution networks to develop and explore the underdeveloped markets of Asia and Latin America. To break into middle-income and emerging markets, market companies are also concentrating on raising awareness, lowering the price of EMR software and related services, and fusing EMR with contemporary technologies.

Microsoft Corp. acquired Nuance Communications, Inc. in April 2021 to empower healthcare providers with the power of ambient clinical intelligence and other Microsoft cloud services.
Capital Health, a regional leader in providing cutting-edge, high-quality patient care, introduced a new electronic health record (EGR) in the acute care divisions of both of its hospitals in February 2021 to better serve its patients.
The “Patient” database personal health record (PHR) of the patient will now be able to safely transfer the patient’s existing health records from the “Patient” database onto the Apple Health app, according to a May 2021 announcement from DrChrono. This should simplify the procedure and make it easier to access medical data more quickly.

Key Segments Covered in Global Electronic Medical Records Industry Study

By Product Type:

Hospital EMR
Ambulatory EMR

By Component:

EMR Software
EMR Services

By Application:

Client Server Setup EMR
Hybrid Server Setup EMR
Cloud Based EMR

By End User:

Hospitals
Specialized Clinics
General Physician Clinics
Ambulatory Surgical Centers

Grab Your Report on Discount Before It’s Gone!
https://www.futuremarketinsights.com/request-discount/rep-gb-387
Author

Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Global Peptide Therapeutics Industry on a Soaring Trajectory: Set to Reach US$106 Billion by 2033 at a 10.8% CAGR | FMI

The Global Peptide Therapeutics Industry is experiencing a remarkable surge, fueled by its growing significance in the pharmaceutical landscape. A recent market analysis reveals the industry’s current valuation at US$38 billion in 2023. It’s projected to reach a staggering US$106 billion by 2033, reflecting a robust Compound Annual Growth Rate (CAGR) of 10.8%. This upward trajectory underscores peptide therapeutics’ escalating significance and potential within the global pharmaceutical landscape. The industry’s growth is fueled by cutting-edge research, innovation, and a growing demand for effective, precision-targeted treatment options.

Peptide medicines have been used to treat metabolic illnesses for over a century. Peptide drugs offer numerous advantages over tiny chemical compounds, resulting in huge demand across geographies.

Here are some of the key advantages of the Global Peptide Therapeutics Industry :

They are precise and have fewer side effects than chemical compounds.
They can be delivered orally, nasally, or topically, which makes them more convenient to administer.
They are more stable in the body and have a longer half-life than chemical compounds.

Further, peptide therapeutics can be a preferred alternative to small molecule and biological therapeutics. All of these factors have led to an upsurge in research and investments in peptide drug recovery over the last ten years and are expected to bode well for the future prospects of the market.

Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-1038

Again, surging incidences of metabolic disorders and the high prevalence of cancer propel the demand for investments in research and development activities in the field of peptide therapies. These illnesses are the prime cause of death and disability all over the world. As a result, there is a greater demand for the development of peptide therapeutics. Peptide-based drug delivery for cancer cells coupled with enhancements in the next-generation therapeutics will presumably supplement the market expansion of peptide therapeutics. In addition to this, there’s a rise in interest in therapeutic peptide research due to commercial reasons. Thus, it is presumed that peptide drug recovery will play a crucial role in the healthcare industry.

“Heightened application of peptides in the treatment of diabetes and cancer will likely augment the sales of peptide therapeutics in the global market over the forecast period,” says an FMI analyst.

Global Peptide Therapeutics Industry Key Takeaways:

The popularity of oral peptide-based drugs generates attractive market opportunities.
Peptide-based therapeutics will continue to gain momentum in Cosmeceuticals.
Government support to aid market growth in North America.
India will offer various lucrative opportunities to the peptide therapeutics industry.
Based on the route of administration, the parenteral route segment will continue to gain preference during the assessment period.

Competitive Landscape from the Global Peptide Therapeutics Industry :

Eli Lilly and Company, AstraZeneca plc, Merck & Co., Inc., Ipsen S.A, Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd., among others, are some of the major players in the peptide therapeutics industry that are profiled in the full version of the report.

In a moderately competitive market, major players are concentrating on market expansion activities. These organizations are engaging in distribution agreements, white space exploration, and collaborative ventures. The more established businesses are focusing on working with local players to expand their production capacities and improve their regional presence.

More Insights into the Global Peptide Therapeutics Industry Report

In its latest report, FMI offers an unbiased analysis of the global peptide therapeutics industry, providing historical data from 2014 to 2021 and forecast statistics for 2022 to 2025. To understand the global market potential, growth, and range, the market is segmented based on application (cancer, cardiovascular diseases, central nervous systems, metabolic disorders, infections, hematological disorders, gastrointestinal disorders, dermatology, respiratory disorders, acromegaly, other applications), route of administration (parenteral route of administration, mucosal route of administration, oral route of administration, transdermal route of administration), drug type (branded drugs, generic/ biosimilar drugs), and region.

According to the latest FMI reports, based on region, the peptide therapeutics market in North America is expected to dominate the market over the forecast period. A surge in government investments as well as an increase in industry spending on research and development activities in peptide therapeutics is driving the regional market growth. This market is further supported by the target market expansion in the United States. Owing to the high prevalence of cancer along with increasing research and development activities, the U.S. peptide therapeutics market is expected to witness impressive growth over the forecast period.

In India, the peptide therapeutics industry is anticipated to gain many profitable future prospects. The rising adoption of synthetic peptide drugs in India is likely to propel the market growth in this region. Rising incidences of chronic illnesses and an aging population also contribute to market growth. Based on the segmentation, based on the route of administration, the parenteral route will continue to gain momentum over the forecast period.

Access Exclusive Market Insights – Purchase Now
https://www.futuremarketinsights.com/checkout/1038

Global Peptide Therapeutics Industry Key Segments:

By Application:

Cancer
Cardiovascular Diseases
Central Nervous Systems
Metabolic Disorders
Infections
Hematological Disorders
Gastrointestinal Disorders
Dermatology
Respiratory Disorders
Acromegaly
Other Applications

By Route of Administration:

Parenteral Route of Administration
Mucosal Route of Administration
Oral Route of Administration
Transdermal of Route Administration

By Drug Type:

Branded Drugs
Generic/Biosimilar Drugs

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Global Cardiopulmonary Bypass System Market Growth, Forecasted to Reach USD 270.9 Million by 2033 at a 3.2% of CAGR

The cardiopulmonary bypass systems market is anticipated to have consistent growth over the next ten years, increasing from an estimated USD 197.3 million in 2023 to an estimated USD 270.9 million by 2033 in terms of valuation. Over the course of the predicted period, this growth translates into a compound annual growth rate (CAGR) of 3.2%. Cardiopulmonary bypass devices sold worldwide had a net worth of about USD 173.9 million in 2018.

Heart valve replacement or repair, coronary artery bypass grafting (CABG), and other difficult cardiovascular surgeries need the use of cardiopulmonary bypass devices, which support the heart and lungs during the surgery. These systems ensure that blood is circulated throughout the body with oxygen by temporarily taking over the role of the heart and lungs.

It is projected that the need for cardiopulmonary bypass equipment would increase because to the growing expenses associated with treating major illnesses including heart diseases. However, it is expected that the unfavorable consequences of bypass surgery may hinder the adoption of these devices. On the other hand, it is anticipated that the quick advancement of technology and the rise in surgical operations would spur market growth and present market participants with fresh prospects.

Request Your Detailed Report Sample With Your Work Email:
https://www.futuremarketinsights.com/reports/sample/rep-gb-5855

Supporting Heart Health: Cardiopulmonary Bypass Systems Play a Vital Role

The global cardiopulmonary bypass system market is experiencing continued growth, driven by the increasing need for effective tools in cardiac surgery. Cardiopulmonary bypass systems play a critical role in open-heart surgery by temporarily taking over the functions of the heart and lungs, allowing surgeons to operate on a still heart.

Market Growth Fueled by Multiple Factors:

Several factors are contributing to the growth of the cardiopulmonary bypass system market:

Increased Focus on Cardiac Care: Rising healthcare expenditure directed towards combating heart disease, a leading global health concern, is creating a greater demand for advanced cardiac surgical procedures.
Technological Advancements: The market is continuously evolving with the development of innovative bypass systems. Roller pumps, for example, are gaining traction due to their affordability, ease of use, and reliable flow management.
Expanding Surgical Needs: The growing number of lung transplant procedures, particularly en-bloc double-lung transplants, is driving the demand for cardiopulmonary bypass systems to support these complex surgeries.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-5855

Key Takeaways:

The global cardiopulmonary bypass system market is expected to reach US$270.9 million by 2033, reflecting a rise from US$197.3 million in 2023.
This growth is projected at a steady compound annual growth rate (CAGR) of 3.2% throughout the forecast period.
Rising healthcare spending on cardiac procedures and advancements in technology are key drivers for market expansion.

The Cardiopulmonary Bypass System Market:

Minnetronix Inc.
Transonic
MAQUET Holding B.V. & Co. KG.
Getinge AB
Terumo Corporation
MicroPort Scientific Corporation
Xenios AG
Nipro Corporation
Eurosets Srl
OriGen Biomedical
Thoratec Corporation
Tianjin Medical
Olympus Corporation
Haemonetics Corporation

Some Recent Developments in the Cardiopulmonary Bypass System Market are:

In June 2014, Sorin Group celebrated the delivery of its 10,000th heart-lung machine (S5 heart-lung machine) to Brigham and Women’s Hospital, Boston, MA, USA. Thuse achieved an exciting milestone that reflects the tremendous trust and collaborative partnership with their customers worldwide.
In October 2021, MicroPort acquired 100% of the equity held by existing shareholders of Hemovent GmbH. Hemovent specializes in the development of ground-breaking Extracorporeal Life Support (ECLS) systems.
In February 2022, Getinge acquired 100% of the equity interest in Talis Clinical LLC, a US-based leading innovator of High Acuity cloud-based software solutions. Talis Clinical’s offer is designed to support and document care throughout the general and cardiac perioperative care process, but also through labor and delivery episodes and critical care support, including ECMO Therapy.
In April 2022, LivaNova initiated the targeted commercial launch of Essenz™. Patient Monitor for cardiopulmonary bypass procedures. The transformative monitoring system uses a patient-tailored approach to improve clinical efficiency and quality of patient care during cardiopulmonary bypass (CPB) procedures.
In January 2021, Eurosets announced the full commercial release (out of the USA) of its novel ECMOlife system for Extracorporeal Life Support (ECLS). ECMOlife expands Eurosets’ portfolio to temporarily support patients in different therapeutic areas, including Extracorporeal Membrane Oxygenation (ECMO) and Mechanical Circulatory Support (MCS).

Key Segments Profiled in the Cardiopulmonary Bypass System Industry Survey Report:

By Product Type:

Conventional
Mini

By Modality:

Standalone
Portable

By End User:

Hospitals
Ambulatory Surgical Centers
Cardiac Research Centers

By Region:

North America
Latin America
Asia Pacific
The Middle East and Africa
Europe

Act Now for Detailed Market Analysis: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/5855

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Bone Growth Stimulators Industry Set to Boom at 10.1% CAGR, Reaching US$5.4 Billion by 2033, Fueled by Rising Fracture Rates

The Global Bone Growth Stimulators Industry is poised for significant growth, driven by the increasing prevalence of bone fractures worldwide. According to a recent report by Future Market Insights (FMI), the market is expected to surge from an estimated valuation of US$2.1 billion in 2023 to a remarkable US$5.4 billion by 2033. This robust growth trajectory reflects a compelling Compound Annual Growth Rate (CAGR) of 10.1%.

This phenomenal growth can be attributed to the rising incidence of bone fractures worldwide. As the need for effective solutions in fracture rehabilitation and treatment intensifies, bone growth stimulators are poised to witness a significant increase in demand.

Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-828

A bone growth stimulator’s best advantage is that it accelerates the entire process of bone healing, resulting in faster recovery, shorter hospitalization, higher cost-effectiveness, and fewer infections.

According to a recent study conducted by the International Osteoporosis Foundation, statistics revealed that more than 200 million people are suffering from osteoporosis. Worldwide, 1 in 3 women over the age of 50 years and 1 in 5 men will experience osteoporotic fractures in their lifetime. These numbers are anticipated to increase at a fast pace in the assessment period, therefore, bolstering the demand for Bone Growth Stimulators worldwide.

Global Bone Growth Stimulators Industry Key Takeaways

Because of an aging population, rapid economic expansion in growing Asia-Pacific (APAC) countries, and an increase in the volume of spine surgeries, the Bone Growth stimulants market in numerous Asia-Pacific countries is likely to grow rapidly over the forecast period.
India is predicted to be the fastest-growing market in APAC, with a CAGR of 11.4%. Growth will be fueled by improvements in the country’s healthcare landscape.
The US market for Bone Growth Stimulators is estimated to exceed US$ 2.2 billion by 2033.
With a rise in medical tourism and a growing demand for less invasive procedures, the United Kingdom is expected to dominate the European Bone Growth Stimulators market in the next years. Sales are expected to account for 20.4% of the global market in 2022.
The hospital segment is estimated to be valued at more than US$ 743 million by 2028.

Global Bone Growth Stimulators Industry Competitive Landscape

The prominent players operating in the Global Bone Growth Stimulators Industry are extensively investing in research and development activities to launch innovative and technologically advanced products that cater to an expanding customer base. In addition to that, dominant market players are heavily investing in mergers, acquisitions, collaborations, and partnerships to strengthen their distribution networks.

Some of the leading companies operating in the Global Bone Growth Stimulators Industry are

Zimmer Biomet Holdings Inc
Bioventus LLC.
DJO Global, Orthofix Holdings, Inc.
Ossatec Benelux Ltd.
IGEA
Ito Co., Ltd.

More Insights into the Global Bone Growth Stimulators Industry

The US is expected to dominate the North American region by garnering maximum sales in the Global Bone Growth Stimulators Industry. The global market is anticipated to account for about 42.5% of the total market share in 2022. According to the CDC, around 1 out of every 4 US adults (23.7%, 58.5 million people) suffer from diagnosed arthritis. The incidence of arthritis and osteoarthritis is predicted to grow in the forthcoming years, which in turn will propel the demand for electrical Bone Growth Stimulators over the assessment period.

The UK is predicted to dominate the European Bone Growth Stimulators market in the forthcoming years, as it accounts for around 20.4% of the total market share in 2022. The growth is attributed to the growing preference for minimally invasive procedures and the rising popularity of medical tourism in the country.

Click Here To Buy Your Full Report
https://www.futuremarketinsights.com/checkout/828

Global Bone Growth Stimulators Industry by Category

Product Type:

Non-Invasive Bone Growth Stimulators
Capacitive Coupling (CC) Devices
Pulsed Electromagnetic Field (PEMF) Devices
Combined Magnetic Field (CMF) Devices
Ultrasound Bone Growth Stimulators
Invasive Bone Growth Stimulators

Application:

Trauma Injury and Fractures
Spinal Fusion
Osteogenesis

End User:

Hospitals
Orthopedic Clinics
Ambulatory Surgical Centers
Homecare settings

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Global Laboratory Information Systems Industry expected to Reach US$3.6 Billion by 2034, Driven by Steady 5.3% CAGR | FMI

The Global Laboratory Information Systems Industry is experiencing a significant upswing, fueled by a robust growth trajectory. According to Future Market Insights (FMI), the market is expected to reach a substantial valuation of US$2,166.3 million by the end of 2024, reflecting a remarkable year-on-year growth rate of 6.0%. This positive trend is expected to continue, with the market projected to reach an impressive US$3,620.3 million by 2034 at a Compound Annual Growth Rate (CAGR) of 5.3%

Germany dominates the European market for laboratory information systems, having accounted for a 28.2% market share in 2014, followed by France. The UK is expected to become a major market for laboratory information systems (LIS) in the coming years.

Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-875

The European laboratory information systems market is segmented based on products, types, components, delivery modes, end users, and countries. The product segment is divided into standalone LIS and integrated LIS. The types included in the report are clinical LIS and anatomical LIS. The components covered in the report are services and software. On-premise, remotely hosted, and cloud-based are delivery modes discussed in the report. The end users’ segment is further classified into clinical diagnostic laboratories, hospitals, anatomical pathology laboratories, blood banks, and molecular diagnostic laboratories. Countries such as Germany, Italy, Spain, the U.K., and France would experience tremendous growth.

The European Commission’s new framework, Horizon 2020 has been the largest ever research and innovation programme in Europe for various fields including life sciences with a budget of $95 billion (€77 billion) from 2014-2020. In October 2017, The European Commission announced its plans to invest $37 billion (€30 billion) in this fund during 2018-2020 including $2.5 billion (€2 billion) to support Open Science, and $740 million (€600 million) for the European Open Science Cloud, European data infrastructure and high-performance computing. Horizon 2020 opened funding opportunities for future and emerging technologies and the ICT Work Programme for life science researchers. Thus, increasing R&D activities and government funding will ultimately boost the demand for effective data management and hence drive the laboratory informatics market in Europe.

Global Laboratory Information System Industry Key Takeaways

Impressive Growth Trajectory: The global laboratory information system market is experiencing a substantial year-on-year growth of 6.0%, reaching a projected valuation of US$ 2,166.3 million by the end of 2024. This surge is indicative of the market’s vitality and potential.
Continuous Evolution with Technology: Technological advancements play a pivotal role in driving the adoption of laboratory information systems. The market is witnessing a transformation with cutting-edge technologies, enhancing operational efficiency and data accuracy in laboratories.
Rising Demand for Efficient Data Management: Laboratories are grappling with vast amounts of data, necessitating sophisticated information systems for efficient management. The demand for robust laboratory information systems is on the rise as organizations recognize the importance of streamlined processes and organized data.
Healthcare Sector as a Key Contributor: The expanding global healthcare industry is a significant catalyst for the laboratory information system market. These systems are becoming indispensable in supporting diagnostic and research activities, aligning with the growing needs of the healthcare sector.
Projected CAGR of 5.3% for the Next Decade: Looking ahead, the market is poised for sustained growth with a projected Compound Annual Growth Rate (CAGR) of 5.3% over the next decade. By 2034, the laboratory information system market is anticipated to achieve a noteworthy valuation of US$ 3,620.3 million.

Competitive Landscape from the Global Laboratory Information Systems Industry:

Top companies in the Global Laboratory Information Systems Industry are constantly releasing new products to increase their market share. They are bolstering their global reach through mergers, partnerships, and acquisitions.

Recent Developments in the Global Laboratory Information Systems Industry:

In September 2022, McKesson Corporation signed an agreement in principle to extend its partnership with CVS Health to distribute pharmaceuticals to mail-order and specialty pharmacies, retail pharmacies, and distribution centers through June 2027.

Global Laboratory Information Systems Industry Key Companies Profiled:

ECerner Corp, Evident, McKesson, Medical Information Technology, Epic Systems Corporation, SCC Soft Computer, Roper Technologies Inc., CompuGroup Medical, and LabWare

Click Here To Buy Your Detailed Report
https://www.futuremarketinsights.com/checkout/875

Key Segments Covered in Global Laboratory Information Systems Industry Research

By Component:

Software
Hardware
Services

By Delivery Mode:

On-premise
Cloud-based

By End-user:

Hospitals
Clinics
Independent Laboratories
Others

By Region:

North America
Latin America
East Asia
South Asia & Pacific
Western Europe
Eastern Europe
Middle East & Africa

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Global Complex Regional Pain Syndrome (CRPS) Market for Remarkable Growth, Expected to Reach USD 129.2 Million by 2033 at a 2.2% of CAGR

The global demand for complex regional pain syndrome market is estimated to be worth around USD 103.7 million in the current year 2023. According to a recent analysis report by FMI, the market is forecasted to expand at a compound annual growth rate (CAGR) of 2.2% during the projection period from 2023 to 2033. The report predicts positive growth for the CRPS market, with a projected valuation of USD 129.2 million by 2033.

Complex regional pain syndrome (CRPS), also known as reflex sympathetic dystrophy (RSD), is a chronic pain condition that typically affects one limb, usually after an injury or trauma. The condition is characterized by intense, continuous pain, swelling, and changes in skin color and temperature in the affected area.

One of the primary factors propelling market expansion is the rise in the number of people with failing back syndrome, chronic pain, and complex regional pain syndrome (CRPS). A chronic pain condition known as complex regional pain syndrome (CRPS) can strike a person all over the body or just in the hands, feet, arms, and legs.

Request Your Detailed Report Sample With Your Work Email:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1708

The increase in the number of persons suffering from complex regional pain syndrome (CRPS), chronic pain, and failing back syndrome is one of the main drivers of market expansion. Complex regional pain syndrome (CRPS) is a chronic pain disorder that can affect one’s entire body or only the hands, feet, arms, and legs.

Both of the two forms of CRPS have the same symptoms and available treatments. Complex Regional Pain Syndrome (CRPS) Type I, sometimes referred to as reflex sympathetic dystrophy, appears following an injury without any nerve damage. Type II CRPS may occur as a result of specific nerve injury or trauma.

Key Takeaways:

The global complex regional pain syndrome (CRPS) market is estimated to reach USD129.2 million by 2033, reflecting a rise from USD103.7 million in 2023.
This growth is projected at a steady compound annual growth rate (CAGR) of 2.2% throughout the forecast period.
The rising prevalence of CRPS and chronic pain conditions are key drivers for market expansion

Market Competition:

Mallinckrodt Pharmaceuticals, GlaxoSmithKline plc. Mylan N.V., Teva Pharmaceutical Industries Ltd., AbbVie, ACTAVIS, Zydus Pharmaceuticals, Inc., Sandoz, and Janssen Global Services, LL. are among the leading companies operating in the market.

Recent Developments in the Complex Regional Pain Syndrome (CRPS) Market

In August 2022, GSK plc announced the New Drug Application (NDA) for momelotinib, a potential new medicine with a proposed differentiated mechanism of action. It may address the significant unmet medical needs of myelofibrosis patients with anemia, which had been accepted by the US Food and Drug Administration (FDA).
In June 2022, Mallinckrodt plc, a global biopharmaceutical company announced the resubmission of the Company’s New Drug Application (NDA) to the USA Food and Drug Administration (FDA) for the investigational agent terlipressin. It helps to treat adults with hepatorenal syndrome (HRS), an acute and life-threatening condition with no FDA-approved treatment.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-1708

Key Companies Profiled:

Mallinckrodt Pharmaceuticals
GlaxoSmithKline plc.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
AbbVie
ACTAVIS
Zydus Pharmaceuticals Inc.
Sandoz
Janssen Global Services LLC.
Medline Plus

Key Segments Profiled in the Complex Regional Pain Syndrome (CRPS) Industry Survey:

By Therapy Type:

Physical Therapy
Therapy via Drugs
- Analgesics
- Antidepressants
- Corticosteroids
- Others
Surgical Sympathectomy
Intrathecal Drug Pumps
Spinal Cord Stimulation

By Route of Administration:

Oral Therapy
Intravenous Therapy

By Distribution Channel:

Hospital Pharmacy
Drug Stores
Retail Pharmacy
E-Commerce

By Region:

North America
Latin America
Europe Complex
Asia Pacific
The Middle East and Africa

Get Full Market Analysis Now: Purchase The Report:
https://www.futuremarketinsights.com/checkout/1708

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Companion Animal Drugs Industry Booming at 4.4% CAGR, Reaching US$59.2 Billion by 2033 | FMI

The ever-deepening bond between humans and companion animals fuels a surge in the Global Companion Animal Drugs Industry. According to a recent industry report, the market is anticipated to reach a remarkable US$59.2 billion by 2033, propelled by a robust Compound Annual Growth Rate (CAGR) of 4.4%. This translates to a significant increase from the US$36.7 billion recorded in 2022, highlighting the growing emphasis on pet health and well-being.

Companion animals, including beloved pets such as dogs, cats, and horses, are integral members of countless families worldwide. The thriving market for companion animal medications underscores the commitment to ensuring their health and well-being. These essential medications are tailored to safeguard pets from infections and various health concerns.

Behind the scenes, companion animal veterinarians emerge as key players in administering these medications. Their expertise is crucial in facilitating the speedy recovery of pets post-surgery, diagnosing and treating ailments, and maintaining overall well-being.

Get a Sample Copy of the Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-1077

Increasing Urbanization and Growing Affluence in Developing Countries to Benefit the Market
Increasing urbanization levels and growing affluence, especially in developing countries, have been driving the adoption of pets, thus leading to increased demand for healthcare products for pets such as companion animal drugs. Continued urbanization has also increased the prevalence of various diseases such as allergies, lower appetite, reduced energy, and behavioral anxieties among small companion animals. This has been driving the demand for innovative classes of medicines such as companion animal drugs.

Upcoming Therapeutic Innovations in Pet Care to Aid Market Growth
Besides traditional drugs, animal health companies have also invested in smart diagnostic care to help prevent diseases before their onset. Companies are also trying to develop generic capabilities to demonstrate bioequivalence to reference prescription drugs in the companion animal drugs market, as many key drugs no longer benefit from intellectual property protection. The development of new animal vaccines and medications are expected to support the growth of the companion animal drugs industry over the forecast period.

Increasing R&D activities and shorter drug-lifecycle are playing an important role in the growth of the companion animal drugs industry. Innovations in companion animal drugs are easier and sustainable for a longer period, while R&D cycle time are shorter (~ three years) in the Companion Animal Healthcare (CAH) industry as compared to human health, ranging between seven and 15 years for other drugs. This increases return on investment in companion animal drugs and leads to faster profits for the market players.

Grab Your Discount Now Before It is Gone!
https://www.futuremarketinsights.com/request-discount/rep-gb-1077

Collaborative Ventures to Promote the Global Companion Animal Drugs Industry Growth
Collaborative ventures such as One Health promote the unification of veterinary and medical sciences, leading to better disease surveillance, control, and education, especially for companion animals such as dogs and cats. One Health venture enables the identification of alteration in infection traveling patterns. The patterns are changing mostly in the case of parasites due to changes in climate and increasing host-vector interactions. Some organizations helping monitor One Health in companion animals are the Companion Animal Parasite Council and European Scientific Counsel Companion Animal Parasites.

Such ventures are expected to complement the growth of the companion animal drugs market.

Low Awareness of Animal Diseases to Hamper the Global Companion Animal Drugs Industry Growth
In many developing countries, people lack awareness regarding certain serious companion animal diseases as opposed to livestock diseases, which are more regularly monitored. This is primarily true about pet vaccinations, which is a mandatory requirement for up to three years. Additionally, parasitic medications for companion animals and livestock are different. Lack of awareness with regards to the differentiation of these medication varieties leads to adverse drug side effects and thus low administration of companion animal medications. Such factors are likely to create a hindrance in the growth of the companion animal drugs market.

Also, the majority of animal healthcare drugs have limited scope for patent extension, primarily due to drug portfolios dominated by drugs that have crossed maturity, which in turn is expected to deter the growth of the companion animal drugs industry over the forecast period.

Key Players in the Global Companion Animal Drugs Industry:

Zoetis Inc.
Merck & Co, Ltd.
Bayer AG
Elanco
Boehringer Ingelheim GmbH (Merial)
Virbac Animal Health
Ceva Santè Animale

Get Your Customized Impactful Report Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-1077

Key Segments Covered in Global Companion Animal Drugs Industry Research

Product:

Antibiotics
Anti-inflammatory
Parasiticides
Heartworm
Behavioral Products
Nutritional Products
Skin Care Products
Vaccines

Distributional Channel:

Veterinary Hospitals
Veterinary Clinics
Pharmacies and Drug Stores

Author

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us: